MENU
+Compare
AVIR
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$3.21
Change
+$0.08 (+2.56%)
Capitalization
271.13M

AVIR stock forecast, quote, news & analysis

Industry: @Biotechnology
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for AVIR with price predictions
Dec 20, 2024

AVIR in upward trend: price may jump up because it broke its lower Bollinger Band on December 05, 2024

AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where AVIR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 18, 2024. You may want to consider a long position or call options on AVIR as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AVIR just turned positive on December 18, 2024. Looking at past instances where AVIR's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

AVIR moved below its 50-day moving average on December 04, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AVIR entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.588) is normal, around the industry mean (14.538). P/E Ratio (0.000) is within average values for comparable stocks, (87.654). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.759). AVIR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (254.760).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AVIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.57B. The market cap for tickers in the group ranges from 151 to 464.4B. NONOF holds the highest valuation in this group at 464.4B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 2%. NEVPF experienced the highest price growth at 260%, while VCNX experienced the biggest fall at -67%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 163%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was 90%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 64
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Franklin Street
Phone
+1 857 284-8891
Employees
75
Web
https://www.ateapharma.com